Importance: Previous studies of prognostic factors of @entity189 of the minor @entity3359 (MSG) have been limited to single-institution studies and small case series. Thus, limited data are available to guide the head and neck oncologist in counseling @entity1 on the prognosis and management of these @entity5 . Objective: To examine 5- and 10-year cause-specific survival (CSS) rates of @entity189 across all histologic subtypes and @entity135 subsites. Design, Setting, and @entity1 : Retrospective, population-based study using National @entity5 Institute's Surveillance, Epidemiology, and End Results (SEER) data from January 1, 1988, through December 31, 2009. The study included 5334 @entity1 diagnosed as having @entity189 and registered in the SEER database. @entity1 without follow-up, diagnostic confirmation, and/or race designation were excluded from the analysis (131 [2.4%]). Final follow-up was completed on December 31, 2009, and data were analyzed from August 5, 2013, to July 1, 2014. Main Outcomes and Measures: Five- and 10-year CSS rates for @entity10479 @entity1 with @entity189 . Cox proportional hazard models were used to estimate adjusted hazard ratios (HRs) and 95% CIs. Results: Among the 5334 @entity1 with @entity189 included, the most common histologic subtypes included @entity3975 (1568 [29.4%]), @entity2347 (1228 [23.0%]), and @entity420 (1313 [24.6%]). The most frequent sites of primary @entity5 were the oral cavity (3132 [58.7%]) and pharynx (1130 [21.2%]). Five-year CSS rate was significantly worse for MSG @entity5 located in the larynx (HR, 2.42; 95% CI, 1.67-3.50) and nasal cavity and/or paranasal sinus (HR, 1.73; 95% CI, 1.29-2.32). Being older than 75 years was associated with a significantly worse 5-year CSS rate (HR, 2.88; 95% CI, 2.05-4.06). Compared with no surgery, local @entity5 destruction (HR, 0.44; 95% CI, 0.30-0.64), partial surgery (HR, 0.33; 95% CI, 0.23-0.47), and total surgery (HR, 0.55; 95% CI, 0.41-0.74) were each found to be a significant positive prognostic factor. No differences were observed in the 5-year hazard of death for race/ethnicity, sex, diagnosis year, or socioeconomic status, and 10-year adjusted HRs were similar to the 5-year patterns. Conclusions and Relevance: This study, to date, represents the largest @entity10479 survival analysis of @entity189 of the MSG. Prognosis is associated with histologic subtype, @entity5 subsite, age at diagnosis, grade, and surgical therapy.

Five- and 10-Year Cause-Specific Survival Rates in XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity135 :: ('MESH:D006258', 'Disease') :: ['head and neck tumor'] @entity10479 :: ('MESH:D065309', 'Disease') :: ['US'] @entity3359 :: ('MESH:D012466', 'Disease') :: ['salivary gland'] @entity3975 :: ('MESH:D018277', 'Disease') :: ['mucoepidermoid carcinoma'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'malignant neoplasms', 'Cancer'] @entity2347 :: ('MESH:D003528', 'Disease') :: ['adenoid cystic carcinoma'] @entity189 :: ('MESH:D002277', 'Disease') :: ['MSG carcinoma', 'carcinoma', 'MSG carcinomas'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma']
@entity189 :: (MESH:D002277,Disease) :: ['Carcinoma of the Minor Salivary Gland']
